Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-44,page-paged-44,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.1,vc_responsive

CLIENT NEWS

 

 

  • Newron Supports Global Rare Disease Day® 2019
    www.newron.com
  • Ergomed and PSR Orphan Experts, Ergomed’s rare disease specialist division, announce 2019 activities in support of Rare Disease Day®
    www.ergomedplc.com
  • Medigene AG: Medigene presents poster on in vitro evaluation of TCR efficacy and toxicity at AACR
    www.medigene.com
  • MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
    www.morphosys.com
  • InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
    www.inflarx.com
  • NOXXON files application for Phase ½ clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients
    www.noxxon.com
  • Medigene announces dosing of first patient in Phase I/II trial with TCR therapy MDG1011 for various blood cancers
    www.medigene.com
  • Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
    www.veronapharma.com
  • Medigene AG: Medigene presents development strategies for TCR therapies at CAR-TCR Summit Europe
    www.medigene.com
  • Medigene AG: European Patent covering TCR library suitable for the development of neoantigen-specific TCRs
    www.medigene.com